WRF
RKDA icon

Waddell & Reed Financial’s Arcadia Biosciences RKDA Stock Holding History

Waddell & Reed Financial’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,736
Closed -$1.63M – 552
2017
Q3 		$1.63M Sell
4,736
-211
-4% -$77.3K ﹤0.01% 502
2017
Q2 		$1.78M Sell
4,947
-555
-10% -$310K ﹤0.01% 514
2017
Q1 		$3M Sell
5,502
-573
-9% -$412K 0.01% 507
2016
Q4 		$4.47M Sell
6,075
-634
-9% -$720K 0.01% 495
2016
Q3 		$10.3M Sell
6,709
-73
-1% -$129K 0.02% 410
2016
Q2 		$14M Hold
6,782
– – 0.03% 359
2016
Q1 		$15.1M Hold
6,782
– – 0.03% 343
2015
Q4 		$16.5M Hold
6,782
– – 0.03% 347
2015
Q3 		$16.5M Hold
6,782
– – 0.03% 331
2015
Q2 		$34.5M Buy
+6,782
New +$42.2M 0.05% 267

Other funds holding RKDA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Waddell & Reed Financial's RKDA Position: Q4 2017 in Review

Waddell & Reed Financial sold out of Arcadia Biosciences (RKDA) in Q4 2017, closing a stake of 4,736 shares — an estimated $1.63M sold.

Waddell & Reed Financial first reported a position in RKDA in Q2 2015 and held it in 10 quarters. The position peaked at $34.5M in Q2 2015. 8 funds tracked by Wall St. Rank hold RKDA as of Q4 2017.

  • Waddell & Reed Financial reported no remaining Arcadia Biosciences position as of Q4 2017 after selling out during the quarter.
  • Waddell & Reed Financial sold 4,736 Arcadia Biosciences shares in Q4 2017, an estimated $1.63M.
  • Waddell & Reed Financial first reported a position in Arcadia Biosciences in Q2 2015 and held it in 10 quarters.
  • Waddell & Reed Financial's Arcadia Biosciences position peaked at $34.5M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2017.

Based on Waddell & Reed Financial's 13F filing for Q4 2017, filed 14 Feb 2018.